Table 1. Baseline characteristics of patients.
| Characteristics | Group A (N = 123) | Group B (N = 53) | p value |
|---|---|---|---|
| Age (years) (SD) | 52.6 (10.2) | 51.7 (9.3) | 0.278c |
| Sex (male/female) | 113/10 | 46/7 | 0.296d |
| Etiology of cirrhosis (HBV/HCV/alcoholic/cholestasis) | 98/14/9/2 | 35/11/6/1 | 0.267d |
| HCC morphology (multifocal/diffuse) | 98/25 | 38/15 | 0.247d |
| HCC maximum diameter (cm) (≥5/<5) | 79/44 | 34/19 | 0.992d |
| Location of TT(LIPV + MPV/RIPV + MPV) | 42/81 | 15/38 | 0.447d |
| Degree of MPVTTa (stenosis/occlusive) | 93/30 | 40/13 | 0.984d |
| AFP (ng/ml) (>400/≤400) | 80/43 | 33/20 | 0.724d |
| Child-Pugh grade (A/B) | 111/12 | 45/8 | 0.306d |
| ECOG PS (0/1/2) | 10/82/31 | 4/31/18 | 0.491d |
| Previous treatment (No/Resection/TACE/RFA/Combination therapyb) | 81/12/16/6/8 | 30/4/10/7/2 | 0.237d |
Abbreviations: AFP Alpha-fetoprotein, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, LIPV left intrahepatic portal vein, MPV main portal vein, MPVTT main portal vein tumor thrombus, RFA radiofrequency ablation, RIPV right intrahepatic portal vein, SD standard deviation, TACE transarterial chembolization, TT tumor thrombus.
a If the diameter of the filling defect exceeded 90% of MPV's on the transverse section image of contrast-enhanced CT or MRI before therapy, this patient's MPV was arbitrarily defined as occlusive.
b Combination therapy means surgical resection followed by TACE or RFA or both and TACE combined with RFA
c Independent t test was used
d Chi-square test was used